908 Devices Inc logo

908 Devices Inc(MASS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
2-STAR RATING
PASS
LAST CLOSE
$9.74
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for MASS

11/13/2026: MASS (2-star) is currently NOT-A-BUY. Pass it for now.

908 Devices Inc is a specialized analytical instruments company developing miniature mass spectrometry and microfluidic technologies for life sciences and defense markets. The company's primary operational strengths lie in its proprietary high-pressure mass spectrometry platform and growing adoption of at-line bioprocessing tools like Rebel and MAVEN. Its core investment narrative centers on capturing decentralized testing demand across biomanufacturing and field safety workflows, though it faces ongoing financial risks from persistent net losses and intense competition from large legacy instrument incumbents. The stock suits growth-oriented investors willing to tolerate high volatility and unprofitability in exchange for technological innovation potential. Key developments to monitor include gross margin trends, consumable pull-through rates, and bioprocessing adoption milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers exposure to expanding life sciences tools and field safety markets with high percentage revenue growth.
Momentum investorMixed fitStrong fit while signal remains positive, as momentum depends heavily on periodic catalysts and broader small-cap biotech sentiment.
Value investorWeak fitThe company lacks current earnings profitability and trades on future technological potential rather than asset or earnings value.
Dividend investorWeak fitThe company pays no dividends and reinvests all available capital into business scaling.
Low-risk investorWeak fitHigh equity price volatility and ongoing net losses create elevated risk profiles unsuited for conservative capital preservation.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences significant price swings driven by shifts in small-cap market sentiment and quarterly earnings reports.
Valuation riskMedium / highValuation is sensitive to top-line growth execution because traditional price-to-earnings metrics remain inapplicable due to ongoing net losses.
Competition risk (large instrument incumbents)HighWell-capitalized legacy analytical instrument giants can outspend 908 Devices in R&D and global marketing.
Business qualityMediumProprietary technology creates defensible niches, though scale is currently restricted by a modest operating footprint.
Dividend incomeLow / noneIncome-focused investors receive zero yield since all earnings are retained for growth.
Execution riskMedium / highSuccess relies heavily on commercial execution and expanding adoption across new bioprocessing and field safety workflows.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 405.01M USD
Price to earnings Ratio -
1Y Target Price 14
Price to earnings Ratio -
1Y Target Price 14
Volume (30-day avg) 387.8K shares
Beta 0.61
52 Weeks Range 5.03 - 13.35
Updated Date 11/15/2026
52 Weeks Range 5.03 - 13.35
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.63

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.7%
Active BUY / eligible
69 / 110
30-Day BUY Count Change
+30
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+4

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -6.66%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
MASS receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
MASS has moderate overall fundamentals (3 stars), with soft financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+49.3%) is partially offset by weak cash generation (FCF margin -43.9%), negative revenue growth (-5.8%), weak profitability (net margin -65.2%).

Financial Health Rating

★★★★★
MASS's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 58.1%). Operating efficiency is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is MASS's strongest growth driver at +49.3% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+20.1%, solid) is also solid, while revenue growth (-5.8%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 89.8% and approximately 67.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 7.41% supports management-shareholder alignment.

Top 5 Institutional Investors

First Light Asset Management, LLC 15.17%
Awm Investment Company Inc 11.78%
ARK Investment Management LLC 4.90%
BlackRock Inc 4.69%
Arnhold & S. Bleichroeder Advisers, LLC 4.49%

Unit Economics (Per $1K Revenue)

★★★★★
MASS generates approximately $477 of gross profit, $-430 of operating income, and $-439 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.20%

Quantitative Style Profile

★★★★★
MASS has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Product RevenueDirect sales of hardware platforms including MX908, Rebel, and ZipChip analytical systems.Core top-line driver representing initial instrument placements in labs and field units.
Consumables and ServicesRecurring sales of microfluidic chips, chemical assay kits, service contracts, and maintenance warranties.Provides a sticky, recurring revenue stream as customers continuously utilize installed instrument fleets.
Geographic MarketsPrimarily North American customers supplemented by international sales through direct channels and global distributors.Geographic exposure is heavily weighted toward domestic government, defense, and biopharma sectors.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 310.52M
Price to Sales(TTM) 6.16
Enterprise Value 310.52M
Price to Sales(TTM) 6.16
Enterprise Value to Revenue 4.72
Enterprise Value to EBITDA -3.15
Shares Outstanding 41.58M
Shares Floating 28.01M
Shares Outstanding 41.58M
Shares Floating 28.01M
Percent Insiders 7.41
Percent Institutions 89.77

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.